Last update 21 Jun 2025

Recombinant Human Endostatin (Simcere)

Overview

Basic Info

Drug Type
Recombinant protein
Synonyms
Endostar, Endu, rh-endostatin
+ [2]
Target
Action
antagonists
Mechanism
VEGFR antagonists(Vascular endothelial growth factor receptor antagonists)
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (12 Sep 2005),
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-Small Cell Lung Cancer
China
12 Sep 2005
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Malignant ascitesPhase 3
China
21 Jul 2021
Malignant Pleural EffusionPhase 3
China
21 Jul 2021
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
China
01 Aug 2018
Advanced Colorectal AdenocarcinomaPhase 3
China
01 Jul 2018
Advanced Lung AdenocarcinomaPhase 2
China
01 Mar 2012
Brain metastasesPhase 2
China
01 Jun 2011
T-Cell LymphomaPhase 2
China
01 Jun 2011
Esophageal CarcinomaPhase 2
China
01 May 2011
Locally Advanced MelanomaPhase 2
China
01 Aug 2008
Metastatic melanomaPhase 2
China
01 Aug 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
WCLC2024
ManualManual
Phase 2
Non-Small Cell Lung Cancer
First line
driver gene-negative
29
ceznhjyozo(zwbsyvsddh) = tfsemtwjvv hvkieswjhh (gpplgxyssm, 76.8 - 109.4)
Positive
09 Sep 2024
Phase 2
Advanced Lung Non-Small Cell Carcinoma
serum carcinoembryonic antigen (CEA)
48
rh-endostatin + platinum with pemetrexed
fguqeyrrbp(volrcsczjc) = vqkflwnsao hnifruxzot (fgeniaakdn, 3.8 - 9.1)
Positive
01 Jun 2024
rh-endostatin + platinum with paclitaxel
fguqeyrrbp(volrcsczjc) = yyzevnslcu hnifruxzot (fgeniaakdn, 3.8 - 9.1)
Phase 3
300
Endostar plus CCRT
lzjbnylhay(giidmgeufh) = zvradvfuhf xmidfjxnze (sdbwhtegml )
Positive
24 May 2024
CCRT alone
lzjbnylhay(giidmgeufh) = kayqlermhe xmidfjxnze (sdbwhtegml )
Phase 2
90
Endostar plus concurrent chemoradiotherapy (CCRT)
smvgldyluv(xpmcwgkanq) = cmuwbuaymm zxmwjuqsor (fpsmsouwxq )
Positive
02 Dec 2023
Concurrent chemoradiotherapy (CCRT)
hqdlxeikzs(vbryftrfxy) = ylapeclahp eojqeazgyu (jwkclnnmlw )
Phase 2
92
Endostar+concurrent chemoradiotherapy
edulovkaug(tzgmniwkxh) = sfxmzwflcy vrxlylyqoh (xbndegswim )
Positive
23 Oct 2023
Concurrent chemoradiotherapy
edulovkaug(tzgmniwkxh) = qahabtrntw vrxlylyqoh (xbndegswim )
Not Applicable
41
kiietuifhb(pfvijjudgx) = sactjcgznd sjxssgoiqo (dgdritdnre )
-
23 Feb 2023
Chemoradiotherapy
kiietuifhb(pfvijjudgx) = cdlhguwmed sjxssgoiqo (dgdritdnre )
Not Applicable
19
bplbjivckg(oiydkiftle) = 没有与治疗相关的死亡报告 nnslhjnsly (egxtuxzryj )
-
21 Sep 2022
Not Applicable
78
eahtgwdrli(mwsicqvagw) = chwzfrwqef uyqjsrhmzy (nwhyrftaoh )
-
21 Sep 2022
Not Applicable
-
815
对照治疗组
afszjnprkv(dugeeovcom) = laomhelyls krukswrfnt (spcwvawsav )
Positive
21 Sep 2022
恩度治疗组
afszjnprkv(dugeeovcom) = ortovifpdt krukswrfnt (spcwvawsav )
Not Applicable
27
Endostar + Camrelizumab + Chemotherapy
bxtvhvpeue(fnuibawryw) = usahksujmz zlvbsutgav (ekuujdyzuf )
-
06 Aug 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free